March 14, 2025
Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout
Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
White House pulls Weldon’s nomination to lead CDC at last minute
Weldon, nomination, Centers for Disease Control and Prevention (U.S.), Confirmation, Vaccines, Weldon ‘s, Senate
Six Payer Trends Shaping Market Access in 2025
Market, trends qualifier, Access, Enrollment, 2025, payer, Shapes, payers, Artificial Intelligence
New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision
Uplizna, Myasthenia Gravis, Effectiveness, Improvement
Mallinckrodt, Endo set for $6.7B merger
pharmaceutical merger, opioid litigation, generics, injectables, synergies